Indian Pharma Sector Sees Q3 Deal Surge Worth $3.5 Billion

In the third quarter of 2025, India's pharmaceutical and healthcare sector witnessed 72 transactions worth USD 3.5 billion. This included significant acquisitions and IPOs, with private deals making up USD 3 billion. The sector's growth was driven by large-value deals and strategic consolidations, reflecting strong investor confidence.

The Indian pharmaceutical and healthcare sector experienced a significant surge in deal activity in the third quarter of 2025, with a total of 72 transactions amounting to USD 3.5 billion, according to Grant Thornton Bharat's latest dealtracker report.

This robust performance included three IPOs valued at USD 428 million and a QIP of USD 88 million. Notably, private transactions contributed USD 3 billion across 68 deals, indicating a remarkable rebound in investor interest.

Highlighted by seven major deals totaling USD 2.6 billion, the sector's vitality was further underscored by Torrent Pharma's USD 1.4 billion acquisition of a 46% stake in JB Chemicals & Pharmaceuticals. This reflects growing confidence in India's life sciences and a focus on innovative, scale-driven investments.

(With inputs from agencies.)